Related Experiment Video
Updated: Mar 15, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
SCARB2/LIMP2 deficiency in action myoclonus-renal failure syndrome
Leanne Dibbens1, Michael Schwake2, Paul Saftig3
1Epilepsy Research Group, School of Pharmacy and Medical Sciences, University of South Australia, and Sansom Institute for Health Research, South Australia, Australia.
Abstract:
Action myoclonus-renal failure syndrome (AMRF) is an autosomal recessive progressive myoclonus epilepsy (PME) associated with renal dysfunction that appears in the second or third decade of life and that is caused by loss-of-function mutations in the SCARB2 gene encoding lysosomal integral membrane protein type 2 (LIMP2). Recent reports have documented cases with PME associated with SCARB2 mutations without renal compromise. Additional neurological features can be demyelinating peripheral neuropathy, hearing loss and dementia. The course of the disease in relentlessly progressive. In this paper we provide an updated overview of the clinical and genetic features of SCARB2-related PME and on the functions of the LIMP2 protein.
Insights
Action myoclonus-renal failure syndrome (AMRF) is a genetic epilepsy linked to SCARB2 gene mutations. This overview details its clinical and genetic aspects, including neurological symptoms and LIMP2 protein functions.
Area of Science:
- Genetics
- Neurology
- Molecular Biology
Background:
- Action myoclonus-renal failure syndrome (AMRF) is a rare, inherited neurological disorder.
- It is characterized by progressive myoclonus epilepsy (PME) and renal dysfunction.
- AMRF arises from loss-of-function mutations in the SCARB2 gene, which encodes lysosomal integral membrane protein type 2 (LIMP2).
Purpose of the Study:
- To provide an updated overview of SCARB2-related PME.
- To summarize the clinical and genetic features of this condition.
- To discuss the known functions of the LIMP2 protein.
Main Methods:
- Literature review of clinical cases and genetic studies.
- Analysis of SCARB2 gene mutations and their impact.
- Review of LIMP2 protein functions in cellular pathways.
Main Results:
- SCARB2 mutations cause PME, sometimes without renal compromise.
- Neurological manifestations include peripheral neuropathy, hearing loss, and dementia.
- The disease course is relentlessly progressive.
Conclusions:
- SCARB2-related PME is a distinct PME subtype with a variable clinical spectrum.
- Understanding LIMP2 protein function is crucial for elucidating disease mechanisms.
- Further research is needed to explore therapeutic strategies for SCARB2-related PME.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cross-bridge Cycle
Lysosomal Hydrolases
Satellite Stem Cells and Muscular Dystrophy
Antihypertensive Drugs: Potassium-Sparing Diuretics

